Raymond James Weighs in on Profound Medical Corp.’s FY2026 Earnings (TSE:PRN)

Profound Medical Corp. (TSE:PRNGet Rating) – Research analysts at Raymond James dropped their FY2026 EPS estimates for Profound Medical in a research report issued on Monday, July 18th. Raymond James analyst R. Sarugaser now forecasts that the company will post earnings per share of $0.87 for the year, down from their prior forecast of $0.95. The consensus estimate for Profound Medical’s current full-year earnings is ($1.19) per share.

Profound Medical Price Performance

TSE:PRN opened at C$9.15 on Tuesday. Profound Medical has a 1-year low of C$8.00 and a 1-year high of C$22.63. The company has a current ratio of 18.32, a quick ratio of 16.07 and a debt-to-equity ratio of 1.79. The firm has a fifty day simple moving average of C$9.96 and a 200 day simple moving average of C$11.02. The stock has a market capitalization of C$190.14 million and a PE ratio of -4.62.

Profound Medical (TSE:PRNGet Rating) last released its earnings results on Monday, May 9th. The company reported C($0.51) earnings per share for the quarter, beating the consensus estimate of C($0.57) by C$0.06. The firm had revenue of C$1.73 million during the quarter, compared to the consensus estimate of C$1.89 million.

Profound Medical Company Profile

(Get Rating)

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland.

Read More

Earnings History and Estimates for Profound Medical (TSE:PRN)

Receive News & Ratings for Profound Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profound Medical and related companies with MarketBeat.com's FREE daily email newsletter.